S&P 500   5,018.03 (+0.14%)
DOW   37,952.09 (+0.47%)
QQQ   421.92 (-0.35%)
AAPL   165.93 (-0.66%)
MSFT   403.98 (-0.07%)
META   497.10 (-0.94%)
GOOGL   155.28 (-0.47%)
AMZN   177.49 (-0.97%)
TSLA   150.32 (+0.26%)
NVDA   841.05 (-0.67%)
AMD   150.98 (-2.64%)
NIO   3.92 (-2.00%)
BABA   68.90 (+0.03%)
T   16.36 (+0.18%)
F   12.12 (+0.50%)
MU   110.35 (-1.41%)
GE   153.02 (+0.05%)
CGC   8.11 (+3.58%)
DIS   112.06 (-0.33%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.35 (+0.40%)
XOM   119.54 (+0.86%)
S&P 500   5,018.03 (+0.14%)
DOW   37,952.09 (+0.47%)
QQQ   421.92 (-0.35%)
AAPL   165.93 (-0.66%)
MSFT   403.98 (-0.07%)
META   497.10 (-0.94%)
GOOGL   155.28 (-0.47%)
AMZN   177.49 (-0.97%)
TSLA   150.32 (+0.26%)
NVDA   841.05 (-0.67%)
AMD   150.98 (-2.64%)
NIO   3.92 (-2.00%)
BABA   68.90 (+0.03%)
T   16.36 (+0.18%)
F   12.12 (+0.50%)
MU   110.35 (-1.41%)
GE   153.02 (+0.05%)
CGC   8.11 (+3.58%)
DIS   112.06 (-0.33%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.35 (+0.40%)
XOM   119.54 (+0.86%)
S&P 500   5,018.03 (+0.14%)
DOW   37,952.09 (+0.47%)
QQQ   421.92 (-0.35%)
AAPL   165.93 (-0.66%)
MSFT   403.98 (-0.07%)
META   497.10 (-0.94%)
GOOGL   155.28 (-0.47%)
AMZN   177.49 (-0.97%)
TSLA   150.32 (+0.26%)
NVDA   841.05 (-0.67%)
AMD   150.98 (-2.64%)
NIO   3.92 (-2.00%)
BABA   68.90 (+0.03%)
T   16.36 (+0.18%)
F   12.12 (+0.50%)
MU   110.35 (-1.41%)
GE   153.02 (+0.05%)
CGC   8.11 (+3.58%)
DIS   112.06 (-0.33%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.35 (+0.40%)
XOM   119.54 (+0.86%)
S&P 500   5,018.03 (+0.14%)
DOW   37,952.09 (+0.47%)
QQQ   421.92 (-0.35%)
AAPL   165.93 (-0.66%)
MSFT   403.98 (-0.07%)
META   497.10 (-0.94%)
GOOGL   155.28 (-0.47%)
AMZN   177.49 (-0.97%)
TSLA   150.32 (+0.26%)
NVDA   841.05 (-0.67%)
AMD   150.98 (-2.64%)
NIO   3.92 (-2.00%)
BABA   68.90 (+0.03%)
T   16.36 (+0.18%)
F   12.12 (+0.50%)
MU   110.35 (-1.41%)
GE   153.02 (+0.05%)
CGC   8.11 (+3.58%)
DIS   112.06 (-0.33%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.35 (+0.40%)
XOM   119.54 (+0.86%)
Free Trial
NASDAQ:FSTX

F-star Therapeutics (FSTX) Stock Price, News & Analysis

→ I’m officially sounding the alarm. (From Altimetry) (Ad)
Free FSTX Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$7.12
▼
$7.12
50-Day Range
$4.42
▼
$7.12
52-Week Range
$2.07
▼
$7.12
Volume
N/A
Average Volume
709,213 shs
Market Capitalization
$156.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
FSTX stock logo

About F-star Therapeutics Stock (NASDAQ:FSTX)

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

FSTX Stock News Headlines

July 20, 2023 | dailymail.co.uk
Adam22's porn star wife Lena The Plug ADMITS she enjoyed sex with other man MORE than husband's
July 12, 2023 | finance.yahoo.com
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US
April 19, 2024 | Altimetry (Ad)
I’m officially sounding the alarm.
AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.
July 11, 2023 | dailymail.co.uk
Twitch star Amouranth reveals she has been diagnosed with 'late stage ovarian failure' at AGE 29 - after 'shrugging off confusing mental and physical symptoms' for MONTHS
June 26, 2023 | startribune.com
Douglas F. Mayo
June 2, 2023 | finance.yahoo.com
Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors
April 24, 2023 | sfgate.com
F. Murray Abraham apologizes after sexual misconduct allegations
March 8, 2023 | businesswire.com
invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.
April 19, 2024 | Altimetry (Ad)
I’m officially sounding the alarm.
AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.
March 7, 2023 | finanznachrichten.de
F-star Therapeutics, Inc.: F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
March 7, 2023 | msn.com
F-star Therapeutics surges as buyer Sino Biopharma gains CFIUS approval
March 7, 2023 | marketwatch.com
F-star Therapeutics Shares Rally After Cfius Clears Takeover >FSTX
March 7, 2023 | msn.com
Why F-Star Therapeutics Shares Are Moving Higher
March 7, 2023 | finance.yahoo.com
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
March 7, 2023 | msn.com
F-Star Therapeutics Blasts Up as Merger Deal Goes Through
March 7, 2023 | finance.yahoo.com
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
March 7, 2023 | msn.com
F-star Therapeutics surges on report sale to Sino Biopharma close to CFIUS approval
February 25, 2023 | seekingalpha.com
F-star Therapeutics jumps as it extends walk date with buyer to `finalize' CFIUS agreement
February 25, 2023 | morningstar.com
F-star Therapeutics Inc Ordinary Shares
February 23, 2023 | msn.com
F-star Therapeutics jumps as it extends walk date with buyer to `finalize" CFIUS agreement
February 22, 2023 | finance.yahoo.com
While institutions own 48% of F-star Therapeutics, Inc. (NASDAQ:FSTX), retail investors are its largest shareholders with 49% ownership
February 9, 2023 | msn.com
F-star Therapeutics gains after deal termination date with buyer extended again
February 8, 2023 | msn.com
F-star Therapeutics gains as buyer Sino Biopharma cancels Shanghai listing
February 1, 2023 | msn.com
F-star Therapeutics up 18% as it extends end date of merger with invoX Pharma
January 26, 2023 | finanznachrichten.de
F-star Therapeutics, Inc.: invoX Pharma and F-star Therapeutics issue Joint Statement
January 26, 2023 | seekingalpha.com
FSTX F-star Therapeutics, Inc.
January 26, 2023 | msn.com
F-star Therapeutics partly pares loss as buyer says in active talks with CFIUS (update)
See More Headlines
Receive FSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for F-star Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FSTX
CUSIP
N/A
CIK
1566373
Web
www.f-star.com
Phone
441223497400
Fax
508-381-0347
Employees
84
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-31,280,000.00
Net Margins
N/A
Pretax Margin
-213.97%
Return on Equity
-57.08%
Return on Assets
-42.40%

Debt

Debt-to-Equity Ratio
0.15
Current Ratio
3.38
Quick Ratio
3.38

Sales & Book Value

Annual Sales
$21.17 million
Price / Sales
7.39
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.70 per share
Price / Book
1.51

Miscellaneous

Outstanding Shares
21,980,000
Free Float
21,279,000
Market Cap
$156.50 million
Optionable
Not Optionable
Beta
0.85
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Eliot Richard Forster
    President, Chief Executive Officer & Director
  • Darlene M. Deptula-Hicks
    Chief Financial Officer, Treasurer & Secretary
  • Louis KayitalireLouis Kayitalire
    Chief Medical Officer
  • Neil Brewis
    Chief Scientific Officer
  • James Sandy
    Chief Development Officer

Key Competitors

View All Competitors

FSTX Stock Analysis - Frequently Asked Questions

How were F-star Therapeutics' earnings last quarter?

F-star Therapeutics, Inc. (NASDAQ:FSTX) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.58) by $0.06. The firm had revenue of $0.75 million for the quarter, compared to analyst estimates of $7.18 million.

This page (NASDAQ:FSTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company